256 The TIGIT/CD226/CD155 axis and the effects of combining PD-1/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models

• Ana Anderson,
• David Reardon,
• Bryan Iorgulescu,
• Gordon Freeman,
• Prafulla Gokhale,
• Max Klapholz,
• Michael Poitras,
• Benjamin Eschle

Affiliations

Ana Anderson

Aff1 grid.62560.370000000403788294Center for Neurologic Diseases Brigham & Women`s Hospital Boston MA USA

David Reardon

2Dana Farber Cancer Institute, Boston, MA, USA

Bryan Iorgulescu

Dana-Farber Cancer Institute, Boston, MA, USA

Gordon Freeman

5Dana-Farber Cancer Institute, Boston, MA, USA

Prafulla Gokhale

1Dana-Farber Cancer Institute, Boston, MA, USA

Max Klapholz

2University of Pennsylvania, Philadelphia, PA, USA

Michael Poitras

1Dana-Farber Cancer Institute, Boston, MA, USA

Benjamin Eschle

1Dana-Farber Cancer Institute, Boston, MA, USA